Business Context and Reporting Period
This Form 8-K, filed on April 5, 2023, by Oncocyte Corporation (trading symbol: OCX), provides preliminary unaudited financial results for the fiscal year ended December 31, 2022. The company develops and commercializes molecular diagnostic tests, including VitaGraft (transplant monitoring), DetermaIO (immunotherapy response), and DetermaCNI (therapy monitoring). The filing also details significant operational changes, including the sale of a majority stake in its subsidiary Razor Genomics and substantial workforce reductions.
Key Financial Metrics
The following table summarizes the company's financial performance for the years ended December 31, 2022 and 2021 (in thousands, except percentages):
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total Revenue | $5,631 | $7,727 | -27% |
| Revenue from Continued Operations | $958 | $2,198 | -56% |
| Revenue from Discontinued Operations | $4,673 | $5,529 | -15% |
| Net Loss | $(72,902) | $(64,097) | Widened |
| Accumulated Deficit (as of 12/31/22) | $(260.7 million) | N/A | N/A |
| Research & Development Expenses | $7,301 | $5,035 | +45% |
| General & Administrative Expenses | $21,881 | $22,292 | -2% |
Liquidity and Cash Flow: The filing states the company has incurred operating losses and negative cash flows since inception. It finances operations primarily through the sale of common stock. The filing does not provide specific cash balance or operating cash flow figures for the period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 27% to $5.6 million. Revenue from continued operations (Pharma Services and VitaGraft) dropped 56% to $958,000, while discontinued operations (DetermaRx) declined 15% to $4.7 million.
- Increased Net Loss: Net loss increased to $72.9 million from $64.1 million. This was driven by a $18.7 million goodwill impairment loss and a $54.3 million loss from discontinued operations, partially offset by a $31.0 million gain from the change in fair value of contingent consideration.
- Discontinued Operations: Operations related to DetermaRx (via Razor Genomics) are now classified as discontinued following the sale of approximately 70% of Razor's equity in February 2023.
- Workforce Reduction: The company eliminated over 40% of its full-time employees in late 2022, incurring $1.65 million in severance and benefits costs.
Outlook, Risks, and Management Commentary
Strategic Focus: Management is prioritizing near-term revenue generators, specifically VitaGraft and DetermaIO. The company aims to complete the development of DetermaIO for clinical use later in 2023. A prototype for a Research Use Only (RUO) version of VitaGraft is planned for the first half of 2023.
Capital Needs: The company expects to continue incurring losses and negative cash flows. It anticipates needing to raise additional capital through equity or debt offerings to fund operations until revenues are sufficient. There is no assurance that financing will be available on favorable terms.
Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting related to the review process for third-party valuations and insufficient accounting resources. Remediation plans are underway, but effectiveness is not guaranteed.
Nasdaq Compliance: The company's stock transferred to the Nasdaq Capital Market in February 2023. It received an additional 180-day period to regain compliance with the minimum bid price requirement ($1.00 per share for 10 consecutive business days).
Risks: Key risks include the inability to attain profitability, dependence on a small number of diagnostic tests, uncertainty in obtaining Medicare reimbursement, and the potential dilution of shareholders from future capital raises.
Investor Verification Checklist
- Verify the final audited financial statements in the upcoming Form 10-K, as current figures are preliminary and unaudited.
- Confirm the status of Medicare reimbursement applications for VitaGraft and DetermaIO, which are critical for commercial viability.
- Monitor the company's ability to meet the Nasdaq minimum bid price requirement within the 180-day compliance period.
- Assess the progress of remediation efforts for the identified material weakness in internal controls over financial reporting.
- Review the terms and timeline for any future equity or debt financing required to sustain operations.